Home
About
Disclaimer
Privacy

JCS/T2D - We are advocates. We learn. We share. We inform.

Enter Part of Title

Display #

CVS Caremark Faces Lawsuit Over Dropping Zepbound
CVS Shifts to Wegovy as Preferred Obesity Medication, Raising Questions About Access and Affordability
Eli Lilly's Stance on Tirzepatide for Cosmetic Use
Eli Lilly’s Zepbound Outperforms Novo Nordisk’s Wegovy in Head-to-Head Weight Loss Study
FDA Approves Lilly's Tirzepatide for Obesity
FDA Approves Zepbound for Obstructive Sleep Apnea in Adults with Obesity
Lifestyle Changes and Anti-Obesity Medications: A Complementary Approach
Lilly Adds High-Dose Zepbound to Self-Pay Program, Expands Access to All Approved Strengths
Lilly Expands Zepbound Access with Single-Dose Vials at Half Price
Lilly Expands Zepbound Vial Options, Lowers Prices for Self-Pay Patients
Novo Nordisk Launches $499 Cash Program for Wegovy, Matching Eli Lilly’s Zepbound Pricing
Public Perception of Obesity and Weight-Loss Drugs
The Economic Impact of Weight-Loss Drugs: A Trillion-Dollar Boost?
Zepbound Outperforms Wegovy in Head-to-Head Obesity Trial

Articles

Novo Nordisk's Stance on Semaglutide for Cosmetic Use
Exploring the Potential of Tirzepatide for Obstructive Sleep Apnea: A New Horizon in Treatment
Diabetes and Heart Health: A Crucial Connection
Tune H Pers Awarded for Groundbreaking Obesity and Diabetes Research
Revolutionizing Diabetes and Obesity Care with AI at Novo Nordisk
New Research Reveals the Hidden Complexity of Insulin Resistance
Join the 5K@EASD Virtual Run/Walk for Diabetes Awareness 2024
Successfully Completed: Diabetes – A Global Challenge
GLP-1 RAs and Gastroparesis (Stomach Paralysis)
The Mounjaro Supply Challenges: Looking Back and Looking Forward
Navigating Prior Authorization for Type 2 Diabetes Treatments
Tips for Using a OneTouch Verio Flex Meter
Bridging Data and Healthcare in the Nordics
How an Hour-by-Hour View Transforms Time in Range Insights
How GLP-1 Receptor Agonists Can Help You Manage Type 2 Diabetes
Tirzepatide’s Efficacy in Treating Obstructive Sleep Apnea
Understanding the Link Between Type 2 Diabetes and Chronic Kidney Disease
The Manufacturing Costs and Supply Chain Dynamics of Diabetes Drugs
The Potential of GLP-1 Medications for Type 1 Diabetes
FDA's Ongoing Evaluation of GLP-1 RAs: No Clear Link Found Between Medication and Suicidal Thoughts or Actions

News

October 2025

FDA Approves Novo Nordisk’s Oral Semaglutide for Heart Protection in Type 2 Diabetes
Innovent’s Mazdutide Outperforms Semaglutide in Head-to-Head Trial
Lilly’s Oral GLP-1 Outperforms Farxiga in Type 2 Diabetes Trial
Semaglutide’s Heart Benefits Extend Beyond Weight Loss
Terns Ends Development of Oral Obesity Drug After Phase 2 Results

September 2025

CVS Caremark Faces Lawsuit Over Dropping Zepbound
Dexcom Introduces Smart Basal at EASD 2025
Eli Lilly Narrows Focus for Oral GLP-1 Naperiglipron
Lilly’s Oral GLP-1, Orforglipron, Shows Strong Results in Obesity and Diabetes Trials
Novo Nordisk Resubmits Once-Weekly Basal Insulin Awiqli® for FDA Review
Novo Nordisk Survey Links Wegovy® to Reduced “Food Noise” and Improved Well-Being
Novonesis and Novo Nordisk Launch Gut Microbiome Collaboration

August 2025

FDA Approves Wegovy for MASH Treatment
FDA Expands Repatha Access to More High-Risk Adults
Lilly Advances Orforglipron Toward Approval After Third Phase 3 Win
Novo Nordisk Expands $499 Cash-Pay Option to Ozempic
Novo Nordisk Strikes $550M RNA Deal with Replicate Bioscience
Signos Press Release Raises Questions About FDA Clearance Claims
Teva Launches First Generic GLP-1 for Obesity
Wegovy Outperforms Mounjaro in Cardiovascular Outcomes

Top Subjects

Type 2 Diabetes
Novo Nordisk
Semaglutide
Obesity Treatment
GLP-1
Wegovy
Eli Lilly
Tirzepatide
Ozempic
Zepbound
Diabetes
Obesity
FDA Approval
Diabetes Management
Cardiovascular Health
Mounjaro
SELECT Trial
Continuous Glucose Monitoring
GLP-1 Therapy
Obesity Management
Metabolic Health
Orforglipron
Disease Modification
Dexcom
CGM
Rybelsus
Clinical Trials
Oral Semaglutide
FDA
Diabetes Treatment

Contact Us

How many eyes does a typical person have?

Search

Search

You are here:
Home
JCS/T2D - A Diabetes Journey

Copyright © 2025 JCS/T2D - A Diabetes Journey. All Rights Reserved.

Joomla! is Free Software released under the GNU General Public License.